AI Power Squeeze Reshapes Mid-2026 Capital Flows: From Software Premiums to Grid InfrastructureGlobal Report·Jul 21 at 04:13 AMADSK+2.19%AISP-0.99%
ICCM: First FDA-cleared minimally invasive cryoablation device for breast cancer, driving global growthQuartr·Jul 14 at 04:57 PMICCM-4.64%
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® CryoablationPR Newswire·Jul 14 at 07:32 AMICCM-4.64%
IceCure Medical publishes investor presentation on ProSense FDA-cleared cryoablation treatment for low-risk breast cancerPUBT·Jul 12 at 09:08 AMICCM-4.64%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Jul 8 at 04:05 PMAPVO+0.46%BRTX-7.17%
IceCure Medical Notifies Availability of Brazil ProSense Adoption Update Press ReleasePUBT·Jul 6 at 07:13 AMICCM-4.64%
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer | ICCM Stock NewsStockTitan·Jul 5 at 11:11 PMICCM-4.64%
IceCure faces certified class action over alleged discounted private placementPUBT·Jun 26 at 03:31 PMICCM-4.64%
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga_article·Jun 26 at 12:05 PMCELZ-4.00%CRIS+4.71%
IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement | ICCM Stock NewsStockTitan·Jun 24 at 11:12 PMICCM-4.64%
